A Prospective, Multi-centre, Phase IV Clinical Trial to Assess the Safety and Efficacy of Acalabrutinib Capsules in Indian Adult Patients With Chronic Lymphocytic Leukaemia and Relapsed and Refractory Mantle Cell Lymphoma.
Latest Information Update: 17 May 2023
At a glance
- Drugs Acalabrutinib (Primary)
- Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma
- Focus Adverse reactions
- Sponsors AstraZeneca
- 12 May 2023 Status changed from active, no longer recruiting to completed.
- 04 Nov 2022 Planned End Date changed from 3 Oct 2022 to 14 Apr 2023.
- 04 Nov 2022 Planned primary completion date changed from 3 Oct 2022 to 14 Apr 2023.